Share
When you hear the words Alzheimer's disease, what do you think of? The truth is, the picture most of us have of the disease is incomplete. Alzheimer's disease doesn't start when someone starts to lose their memory. It actually starts years – sometimes decades – earlier. The Rethinking Alzheimer's Disease Podcast is an engaging, narrative-style podcast miniseries for those curious or motivated to learn about Alzheimer’s disease. Perhaps you have a family member with Alzheimer’s disease, or ca ...
…
continue reading
Manage episode 513979089 series 2908385
Content provided by Mayo Clinic Laboratories. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Mayo Clinic Laboratories or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Published October 16, 2025
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, discuss recent regulatory and policy developments. Together, they explore:
- FDA rescinds rule on LDTs (00:48): The FDA has officially withdrawn its rule that would allow oversight of laboratory-developed tests (LDTs) as medical devices. The conversation explores what this decision means and what might come next for LDT regulation.
- PAMA reform update and new RESULTS Act (05:13): The newly introduced Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act aims to address reimbursement for laboratory tests.
- Getting engaged (12:37): Why it is important to understand new regulatory policies and help others understand their implications for the industry.
Resources
368 episodes
))
